[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-35781":3,"doc-seo-35781":29},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":13,"seo_description":14,"update_tm":27,"read_time":28},35781,5909877438554,"Maeve","https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272",7,"Healthcare","High dose denosumab Xgeva Associated Medication Related Osteonecrosis of the Jaws","A retrospective analysis evaluates the incidence and clinical characteristics of medication-related osteonecrosis of the jaws (MRONJ) associated with high-dose denosumab (Xgeva®). The study reports results based on 1278 patients and documents related clinical patterns relevant to jaw disease development under this therapy. Publication details include the study timeline from received to accepted and online publication in 2024, supporting evidence synthesis for supportive care in oncology.","","cbCaisriQWT5kSz3","https://ap.wps.com/l/cbCaisriQWT5kSz3","pdf",860656,1,9,"English","en",105,"# Study Overview\n## Incidence and Clinical Characteristics\n## Patient Cohort","[{\"question\":\"What medication relationship is investigated in this study?\",\"answer\":\"The study examines medication-related osteonecrosis of the jaws (MRONJ) associated with high-dose denosumab (Xgeva®).\"},{\"question\":\"How many patients are included in the retrospective analysis?\",\"answer\":\"The analysis includes 1278 patients.\"},{\"question\":\"What key outcomes are reported?\",\"answer\":\"The study focuses on incidence and clinical characteristics of MRONJ in the patient cohort.\"}]",1782594257,23,null]